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Viral hijacking of cellular metabolism
Shivani K. Thaker1†, James Ch’ng2† and Heather R. Christofk1,3,4*
Abstract
This review discusses the current state of the viral
metabolism field and gaps in knowledge that will be
important for future studies to investigate. We discuss
metabolic rewiring caused by viruses, the influence of
oncogenic viruses on host cell metabolism, and the
use of viruses as guides to identify critical metabolic
nodes for cancer anabolism. We also discuss the need
for more mechanistic studies identifying viral proteins
responsible for metabolic hijacking and for in vivo
studies of viral-induced metabolic rewiring. Improved
technologies for detailed metabolic measurements
and genetic manipulation will lead to important
discoveries over the next decade.
Introduction
Although it’s been known for over half a century that
viral infection alters host cell metabolism, the mecha-
nisms and consequences of virus-induced metabolic re-
programming have only begun to be studied in detail
over the past decade (Fig. 1). Viruses clearly rely on host
cell machinery to propagate—they promote anabolism
for generation of macromolecules needed for virion rep-
lication and assembly. Therefore, it is not surprising that
viral infection triggers metabolic reprogramming in host
cells to facilitate optimal virus production. Metabolic
phenotypes conferred by virus infection often mirror
metabolic changes seen in cancer cells, such as upregu-
lation of nutrient consumption and anabolism to sup-
port viral replication or rapid cell growth, respectively.
For example, cancer cells and virus-infected cells com-
monly both exhibit the Warburg effect: increased glyco-
lytic metabolism in the presence of adequate oxygen for
oxidative phosphorylation, to supply reducing equiva-
lents and precursors for macromolecule biosynthesis
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[1, 2]. Increased nucleotide and lipid biosynthesis are
two other metabolic alterations associated with
tumorigenesis and rapid cell proliferation that are also
seen in various virus infections [1–8]. However, it remains
to be determined whether metabolic reprogramming by
cancer-causing viruses contributes to oncogenesis. Here
we discuss what is currently known about the metabolic
reprogramming by different viruses, the effects of onco-
genic viruses on host cell metabolism, and the use of vi-
ruses as a guide to identify critical metabolic nodes for
cancer anabolism. Throughout, we point out gaps in
knowledge and important unknowns in the viral metabol-
ism field that will hopefully be elucidated in future studies.
Virus infection induces metabolic reprogramming
in host cells
In this section, we describe what is currently known
about how different viruses rewire host cell metabolism
to facilitate optimal viral replication. Both DNA and
RNA viruses have been shown to reprogram various as-
pects of host central carbon metabolism, including in-
creased glycolysis, elevated pentose phosphate activity to
support generation of nucleotides, amino acid gener-
ation, and lipid synthesis (Fig. 2). While several viruses
upregulate consumption of key nutrients like glucose
and glutamine and converge on similar metabolic path-
ways for anabolism, the precise metabolic changes in-
duced by specific viruses are often context-dependent
and can vary even within the same family of viruses or
depend on the host cell type that is infected. While im-
proved technologies have enabled a more in-depth ana-
lysis of how different viruses alter host cell metabolism
to promote virus replication, future studies are needed
to further uncover mechanisms involved in viral meta-
bolic reprogramming.
Adenovirus
Adenovirus is a double-stranded DNA virus that relies
entirely on host cell machinery for replication [9].
Several early studies in the 1950s through 1970s de-
scribed increases in glycolysis during adenovirus infec-
tion [10, 11]. However, recent technological advances
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have enabled more detailed analysis of the metabolic
changes induced during adenovirus infection, and poten-
tial mechanisms by which metabolic reprogramming
may occur. Wild-type adenovirus 5 (ADWT) infection
of human breast and bronchial epithelial cells leads to
increased glucose consumption and lactate production
as well as decreased oxygen consumption rates [2]. Glu-
cose is used to generate pentose phosphate pathway in-
termediates and nucleotides during infection, likely to
support viral genome replication [2]. The ADWT-
induced increases in glycolysis are mediated by early
adenovirus gene product E4ORF1 binding to cellular
MYC to direct transcription of specific glycolytic en-
zymes, including HK2 and PFKM, and an adenovirus
containing the D68A point mutation in E4ORF1 that
prevents binding to MYC does not replicate as well as
ADWT [2].
In addition to altering cellular glucose metabolism,
ADWT infection of human bronchial epithelial cells re-
sults in increased glutamine consumption and activity of
glutaminase (GLS) [12]. Glutamine tracing studies show
that glutamine undergoes reductive carboxylation during
ADWT infection, potentially as a source of citrate [12].
Additionally, glutamine is used to generate amino acids
and hexosamine pathway intermediates [12]. These
changes in glutamine metabolism are all dependent on
E4ORF1 binding to cellular MYC. Pharmacologic inhib-
ition of GLS by CB-839 reduces optimal replication of
not only adenovirus, but also diverse viruses including
HSV-1 and influenza A virus [12].
Although adenovirus-encoded E4ORF1 activation of
MYC is responsible for the reported changes in glucose
and glutamine metabolism during viral infection, the re-
duced respiration in adenovirus-infected cells seems to
occur independent of E4ORF1 and MYC. The D68A
mutant adenovirus deficient in E4ORF1 binding to MYC
reduces respiration in infected human breast epithelial
cells [2]. It will be interesting for future studies to iden-
tify the molecular mechanism by which adenovirus alters
host cell respiration and to decipher whether and how
this may be beneficial for viral replication.
Herpes family (HSV-1, HCMV)
Herpesviruses are DNA viruses that undergo both
lytic and latent phases of their viral reproduction
cycle. While there are more than 100 known herpes-
viruses, about eight are known to infect human cells
exclusively, and can lead to latent infection in specific
human tissues [13].
Fig. 1 Metabolic pathways altered by virus infection. Figure includes alterations demonstrated by changes in metabolite levels, flux, and tracing.
*Herpesvirus family; #Flavivirus family; &virus downregulates this metabolic activity; @KSHV upregulates lipid synthesis but downregulates cholesterol
synthesis. Created with BioRender.com
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Herpes simplex virus 1 and 2
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are
common viruses that typically cause cold sores and
genital herpes, respectively. After entry into the host,
both viruses replicate in epithelial cells before ascend-
ing into the neural ganglia where latent infection is
established [13]. More is known about the metabolic
reprogramming conferred by HSV-1 infection than
HSV-2 infection.
HSV-1 alters glucose metabolism variably in different
contexts. A study in the 1960s showed that HSV-1 virus
production is impaired in the absence of glucose in
growth media [14]. HSV-1 infection of human foreskin
fibroblast (HFF) cells by the KOS strain of HSV-1 does
not lead to a change in glucose consumption and lactate
production [3]. However, infection of African monkey
kidney epithelial (Vero) cells by the acyclovir-resistant
AR-29 HSV-1 strain promotes increased glucose con-
sumption and lactate production as well as increased
phosphofructokinase (PFK-1) activity and expression
[15]. The variable metabolic phenotypes may partially be
context-dependent since different cell types and HSV-1
viral strains were used in both studies.
Recent studies utilizing liquid chromatography coupled
to mass spectrometry (LC-MS) and isotope tracers have
analyzed the metabolic changes induced by HSV-1 infec-
tion of host cells. HSV-1 infection leads to increased levels
of glycolytic intermediates upstream of phosphoenolpyr-
uvate (PEP) [3]. Notable metabolic phenotypes of HSV-1
infected cells include increased levels of pentose phos-
phate pathway intermediates and deoxypyrimidines and
increased kinetic labeling of UTP by U-13C5-glutamine,
indicative of elevated de novo pyrimidine nucleotide
synthesis [3]. HSV-1 upregulates pyrimidine nucleotide
biosynthesis by increasing aspartate generation, both
through elevated glucose flux into the TCA cycle through
pyruvate carboxylase (PC) and from glutamine anaplero-
sis, followed by subsequent metabolism by glutamic-
oxaloacetic acid transaminase 2 (GOT2) to form aspartate,
which contributes to the pyrimidine backbone [3, 16].
Consistently, knockdown of PC and GOT2 decrease opti-
mal HSV-1 replication [3]. A long noncoding RNA,
lncRNA-ACOD1, binds GOT2 and enhances its catalytic
activity while deficiency of the lncRNA decreases viral
replication of HSV-1, vaccinia virus, and vesicular stoma-
titis virus [17]. Since aspartate is an important source of
carbons for nucleotide synthesis, knockdown of enzymes
that deplete aspartate, including argininosuccinate synthe-
tase (AS1), increases viral titers by increasing aspartate
availability for virus replication [16].
Since HSV-1 is a large double-stranded DNA virus with a
genome of approximately 152 base pairs, viral replication
necessitates a large pool of nucleotides [18]. Interestingly,
HSV-1 encodes some of its own nucleotide metabolism en-
zymes, including thymidine kinase, dUTPase, uracil-DNA
glycosylase, and ribonucleotide reductase [19]. It has been
hypothesized that HSV-1 has evolved to promote nucleo-
tide biosynthesis in host cells since the virus infects and
Fig. 2 Non-oncogenic viruses and metabolic alterations in host cells during infection
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replicates in non-proliferative cell types such as neurons.
Consistent with evidence of nucleotide metabolism playing
an important role in HSV-1 replication, current first-line
therapeutics to treat HSV infections include nucleoside an-
alogs such as acyclovir and ganciclovir, which exert their ef-
fects on infected cells after being metabolized by viral
thymidine kinase [20]. However, resistance to these conven-
tional drugs has been emerging, and a better understanding
of whether and how drug-resistant HSV strains reprogram
host cell metabolism, including AR-29, a strain of HSV-1
that is resistant to acyclovir, could lend insight to treating
resistant infections [21].
Whether modulation of glycolysis impacts HSV-1 rep-
lication is not completely understood. Treatment of
HSV-infected human embryonic lung cells with 2-
deoxyglucose (2-DG), a commonly used inhibitor of glu-
cose metabolism, leads to reduced glycosylation of viral
glycoproteins and decreased viral-induced cell fusion,
which is important for cell-to-cell spread of HSV [22]. 2-
DG treatment has also been shown to attenuate HSV-1
replication [23, 24], and a clinical trial in which female
patients with genital herpes were treated with either pla-
cebo drug or 2-DG for a 3-week period concluded that
2-DG decreases viral shedding and improves symptoms
[25]. However, this finding was directly challenged by
another group that argued that 2-DG treatment is not
efficacious in reducing HSV-1 and HSV-2 virulence in
mouse and guinea pig models [26]. Inhibition of glycoly-
sis through genetic means may help shed light on
whether or not glucose metabolism is important for
HSV replication. Future studies examining metabolic ef-
fects of different strains of HSV-1 on host cells as well
as tropism based on cell type would enhance under-
standing of HSV-induced metabolic reprogramming.
Human cytomegalovirus
Infection by human cytomegalovirus (HCMV), another
herpesvirus family member, is asymptomatic in immuno-
competent adults but can lead to more serious complica-
tions like retinitis, interstitial pneumonitis, and encephalitis
in immunocompromised patients [27].
HCMV promotes increased glucose consumption
and lactate production in infected human fibroblasts,
and glucose withdrawal during infection reduces virus
replication [3, 28–31]. HCMV promotes increased
glycolytic flux [29], likely through inducing increased
expression of several glycolytic enzymes and activity
of PFK [32]. Mechanistically, HCMV-encoded major
immediate-early protein IE72 alters expression of glu-
cose transporters in infected cells—it eliminates
GLUT1 protein and, by an unknown mechanism, in-
creases mRNA and protein levels of GLUT4, which has
three times higher affinity for glucose than GLUT1 [30].
Treatment of cells with the drug indinavir, thought to
selectively inhibit GLUT4 activity, reduces glucose uptake
and HCMV virus replication [30]. GLUT4 upregulation is
dependent on carbohydrate-response element binding
protein (ChREBP), which is highly elevated at both the
mRNA and protein levels during HCMV infection, and
ChREBP knockdown reduces GLUT4 mRNA levels and
subsequently glucose consumption and lactate production
[33]. ChREBP knockdown in host cells also decreases
HCMV replication [33]. AMP-activated protein kinase
(AMPK) is also more active in HCMV-infected cells,
and blocking AMPK signaling reduces glycolysis in-
duced by infection and virus replication [34].
In addition to promoting increased glucose uptake
and glycolysis, HCMV also promotes increased
U-13C6-glucose labeling of TCA cycle intermediates,
particularly citrate, which is kinetically labeled by glu-
cose more rapidly in HCMV-infected cells compared
to mock controls [29]. Studies with U-13C6-glucose
have shown that an increased fraction of glucose is
used to generate fatty acid and glycerol moieties of
lipids in HCMV-infected cells [3]. Glucose can be
used to form acetyl CoA, which is a critical precursor
for lipid synthesis and can be generated by ATP-
citrate lyase (ACLY) and acetyl-CoA synthetase short-
chain family member 2 (ACSS2) [35]. ACSS2, but not
ACLY, is important for HCMV-induced lipogenesis
and virus replication [35]. HCMV also induces lipo-
genesis and expression of key lipogenic enzymes dur-
ing infection through sterol regulatory element
binding protein 1 and 2 (SREBP1 and 2) cleavage and
activation and induction of PKR-like endoplasmic
reticulum (ER) kinase (PERK) [36, 37].
HCMV infection promotes glutaminolysis in infected
cells [31]. Consistently, the enzyme activities of gluta-
minase (GLS) and glutamate dehydrogenase (GDH) are
also elevated upon HCMV infection [31]. Since glucose
is routed towards lipid synthesis during HCMV infec-
tion, glutamine is used to replenish the TCA cycle in
host cells and contributes to increased ATP production
[31]. Glutamine withdrawal decreases virus titer and
ATP production, both of which can be rescued, at least
in part, by addition of alpha-ketoglutarate, oxaloacetate,
or pyruvate [31].
Flaviviruses
Flaviviruses are a genus of positive, single-stranded RNA
viruses that are typically transmitted to humans through
arthropod vectors, including mosquitoes, and undergo
lytic replication [38]. The Flaviviridae family consists of
viruses known to cause serious diseases, including den-
gue virus (DENV), West Nile virus (WNV), Japanese en-
cephalitis virus (JENV), Zika virus (ZIKV), and hepatitis
C virus.
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Dengue virus
As with many other viruses, DENV infection of primary
HFF cells increases glycolysis and alters levels of glyco-
lytic intermediates compared to uninfected cells [39].
DENV infection of HFFs also induces upregulation of
GLUT1 protein levels and increases in hexokinase 2
(HK2) mRNA and protein levels [39]. Consistently, glu-
cose withdrawal in host HFF cells leads to a nearly 2-log
decrease in DENV replication, and 2-DG treatment of
HFF and immortalized endothelial (TIME) cells during
infection reduces virus replication [39]. Intracellular glu-
tamine and glutamate levels also increase during DENV
infection, although glutamine withdrawal in cell medium
during infection leads to a minimal change in infectious
DENV production [39].
While studies examining glucose utilization during
DENV infection via glucose tracers remain to be com-
pleted, a likely use of glucose is in the TCA cycle and for
citrate production to generate lipids. DENV infection
leads to elevated fatty acid synthase (FAS) activity in
host cells, and radiolabeled acetate and malonyl-CoA
incorporation into lipids increases in infected versus
non-infected host human embryonic lung cells [40].
Mechanistically, DENV nonstructural protein 3 (NS3)
recruits FAS to sites of DENV particle replication and
stimulates FAS activity. Consistently, FAS inhibitors, cer-
ulenin and C75, reduce DENV replication [40]. DENV
also induces autophagy to release free fatty acids and in-
crease cellular β-oxidation during infection via stimula-
tion of AMPK signaling [4, 41]. Other flaviviruses,
including WNV and JEV, have also been shown to rely
on lipid metabolism for optimal replication [42, 43].
Zika virus
ZIKV is a flavivirus that has been emerging as a public
health concern. It can infect a broad range of cell types,
including neural progenitor cells, which may lead to
microcephaly and developmental abnormalities in in-
fected fetuses [44].
Metabolically, ZIKV infection of both human and
mosquito cells leads to increased glycolysis [45]. ZIKV-
infected HFFs use increased glucose to generate TCA
cycle intermediates, whereas infected mosquito cells use
increased glucose for pentose phosphate pathway gener-
ation [45]. Interestingly, nucleotide triphosphates are de-
pleted in human cells but not mosquito cells, leading to
AMPK activation and caspase-mediated cell death in hu-
man cells [45]. The molecular mechanism by which
ZIKV alters specific metabolic pathways in human versus
mosquito cells remains to be determined.
Vaccinia virus
Vaccinia virus (VACV) is a large, enveloped DNA virus
and member of the poxvirus family, which includes the
variola virus that causes smallpox. VACV is unique in
that it replicates in the cytoplasm of the host cell instead
of the nucleus like most DNA viruses [46]. One study
suggested that VACV infection of HFFs increases intra-
cellular glutamine and glutamate levels at multiple time
points post-infection [47]. Consistently, VACV infection
of glutamine-starved cells leads to significant decreases
in virus replication and treatment of VACV-infected
cells with BPTES, a glutaminase inhibitor, also results in
reduced virus titers [47]. Exogenous supplementation of
α-ketoglutarate, oxaloacetate, or pyruvate during VACV
infection in glutamine-depleted media can partially res-
cue the defects in virus replication, suggesting that glu-
tamine is an important anaplerotic substrate for the
TCA cycle during VACV infection. Glutamine with-
drawal has no effect on VACV transcription but signifi-
cantly reduces early and late VACV protein synthesis.
Interestingly, glutamine, but not glucose, is a critical nu-
trient for VACV replication as glucose withdrawal in
VACV-infected cells causes no change in viral yield [47].
Future studies using heavy carbon- and nitrogen-labeled
glutamine tracers would be interesting to further assess
the role of glutamine in VACV-infected cells.
De novo fatty acid (FA) biosynthesis also plays a role
in VACV replication. Inhibition of fatty acid synthase by
C75 and of acetyl-CoA carboxylase (ACC) by TOFA in
VACV-infected cells reduces viral yield, both of which
can be partially rescued by exogenous palmitate, the first
fatty acid generated from FA synthesis and a precursor
to longer fatty acids [48]. Mitochondrial import and β-
oxidation of palmitate is important for VACV replication
since treatment of infected cells with etomoxir, an in-
hibitor of mitochondrial import of long-chain fatty acids,
and trimetazidine, an inhibitor of β-oxidation, both re-
duce viral yield compared to DMSO-treated cells. Con-
sistent with VACV-induced β-oxidation, infection of
HFFs also leads to increased oxygen consumption and
ATP production. Inhibition of mitochondrial import and
β-oxidation mildly reduce viral DNA replication and
protein synthesis; however, VACV-infected BSC40 cells
treated with TOFA and C75 showed decreased viral as-
sembly, suggesting that de novo fatty acid biosynthesis
plays an important role in virion assembly.
While VACV has been shown to induce and rely on al-
tered metabolism in host cells, the mechanisms by which
VACV causes these changes are still being studied. The
VACV genome encodes approximately 200 proteins in-
volved in various processes that assist virus replication. One
study showed that the VACV-encoded C16 protein pro-
motes HIF-1α stabilization through binding to the prolylhy-
droxylase domain-containing protein (PHD)2, a cellular
oxygen sensor [49]. Since HIF-1α is an important cellular
transcription factor for numerous metabolic genes dysregu-
lated in cancers [50], future studies should explore whether
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HIF-1α is responsible for the metabolic changes induced
during VACV infection.
Influenza
Influenza A, which is an RNA virus in the Orthomyxovi-
rus family, causes acute respiratory disease and is a
major public health burden [51].
Influenza A virus has been reported to increase gly-
colysis, enhancing glucose uptake and lactate production
at early time points post-infection, as well as increase
oxygen consumption rates [52–54]. Compared to mock-
infection, influenza A infection leads to elevated levels
of upper glycolytic intermediates and reduced levels of
nucleotide triphosphates at early time points [52].
Pediatric patients with respiratory infections showed
higher PET signal in influenza A-infected lungs com-
pared to lungs that had cleared the infection and tested
influenza negative [54]. Treatment with a putative PI3K/
mTOR inhibitor, BEZ235, decreases glycolysis and re-
duces virus replication at an uncharacterized step fol-
lowing viral genome replication, resulting in decreased
mortality in a mouse model of influenza infection [54].
Miscellaneous viruses
While all the previously mentioned viruses alter the me-
tabolism of host mammalian cells, viruses that infect
invertebrate hosts have also been shown to alter metabol-
ism. The invertebrate virus white spot syndrome virus
(WSSV) that infects shrimp hemocytes induces glycolysis
in infected cells versus normal cells in a PI3K-Akt-mTOR-
dependent manner [55, 56]. DENV infection of mosquito
cells leads to increased lipid biosynthesis in infected cells
[5]. The fact that metabolic reprogramming by viruses is
conserved throughout species, even in invertebrates, pro-
vides further evidence that metabolic reprogramming is
critical for replication of diverse viruses.
Limitations of current studies and future directions
While diverse viruses have been shown to reprogram
host cell metabolism, many of the molecular mecha-
nisms by which viruses induce these changes remain un-
known. A number of viruses, in addition to HSV-1,
encode their own metabolic enzymes—usually involved
in nucleotide biosynthesis—to facilitate viral replication
in host cells. For instance, VACV encodes its own thymi-
dylate kinase, and HSV-1 encodes RRM2. Side-by-side
comparisons of the virally encoded versus human cell
encoded versions of these enzymes may help decipher
potential differences in activity or regulation. For those
viruses that rely on hijacking host cell machinery for
metabolic reprogramming, identifying the viral gene
products that interact with host cell factors to modulate
metabolism will deepen our understanding of viral-
induced changes to host metabolism and may even shed
light on viral tropism.
A major limitation in our current understanding of
viral-induced metabolic reprogramming stems from the
fact that most of the work characterizing viral alterations
to host cell metabolism so far has been carried out in
vitro. However, metabolism in vivo is known to be quite
different from that found in vitro in cell culture condi-
tions. In vivo models to assess metabolic changes in-
duced by virus infection are needed to have a more
accurate understanding of viral metabolism and facilitate
therapeutic antiviral strategies.
Additionally, many viruses, including HSV-1 and
HCMV, undergo both lytic and latent phases of infection
in host cells, but most studies characterizing metabolism
by both viruses have focused only on the lytic phase. De-
termining whether metabolic changes are unique at dif-
ferent phases of infection would be of interest.
The interplay between metabolism and the immune
system during virus infection is also understudied. Since
immune cells also rely on some similar nutrients and
pathways perturbed by viruses, understanding the effects
of modulating metabolic pathways in vivo will be im-
portant in assessing the overall impact to the host.
While glutamine metabolism has been shown to be im-
portant for HSV-1 replication in vitro [31], glutamine
supplementation in HSV-infected mice actually represses
reactivation of HSV-1 since it enhances the activity of
IFN-γ-producing CD8 T cells [57]. Whether or not an
individual’s diet may also impact virus replication would
be an interesting area for further investigation.
Future studies should determine whether viruses dis-
play tropism for specific cell types and cause different
cellular outcomes depending on the metabolic environ-
ment and machinery present in the cells. Hints of this
concept already exist. For example, HSV-1 increases de
novo nucleotide biosynthesis and encodes its own nu-
cleotide metabolism enzymes because HSV-1 infects
neurons, which do not actively divide [3]. On the other
hand, HCMV typically infects growth-arrested cells, like
fibroblasts, and pushes arrested cells into the G1/S cell
cycle phase to promote nucleotide synthesis without
host cell DNA replication [3]. Additionally, it is intri-
guing that infection by the same virus can have contrast-
ing effects on different types of host cells, as is the case
in ZIKV-infected human versus mosquito cells.
Influence of oncogenic viruses on host cell
metabolism
Nearly 10% of all new cancer cases worldwide are attrib-
utable to oncogenic viruses. These viruses include hu-
man papillomavirus (HPV), hepatitis B virus (HBV),
hepatitis C virus (HCV), Epstein-Barr virus (EBV),
Kaposi’s sarcoma-associated herpesvirus (KSHV), and
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human T-cell lymphotropic virus type 1 (HTLV-1)
(Fig. 3) [58]. Another recently discovered oncogenic
virus, Merkel cell polyomavirus (MCPyV), was discov-
ered in 2008 in association with the rare malignancy
Merkel cell carcinoma (MCC) [59]. Still other viruses,
such as adenovirus type 12, that are not known to be
oncogenic in humans have been shown to be capable of
inducing transformation and oncogenesis in other
animals [60].
As our understanding of how viruses contribute to the
development of cancer grows, an emerging area of study
is how oncogenic viruses manipulate the metabolism of
the host cell. The similarities between the metabolic re-
programming that occurs during viral infection and that
which occurs in cancer cells makes the contribution of
viral infection to cancer metabolism an important topic.
In this section, we discuss the metabolic changes that
occur during infection by known oncogenic viruses.
Human papillomavirus
HPV is a double-stranded DNA virus and is the onco-
genic virus found in the largest number of cancer cases,
estimated to cause 4.5% of all cancers worldwide, with
cervical cancer comprising 83% of these cases while
other anogenital cancers and head and neck cancers
make up the rest [61].
Studies suggest that HPV infection produces a number
of viral proteins that affect host cell metabolism. The
HPV viral proteins E6 and E7 augment HIF-1α, which
may result in an enhanced glycolytic phenotype in a
hypoxic solid tumor microenvironment. E6 stabilizes
HIF-1α under hypoxic conditions by inhibiting VHL as-
sociation with and ubiquitination of HIF-1α [62]. In cells
treated with hypoxia mimetic deferoxamine mesylate, E7
is able to enhance HIF-1α activation of target genes [63].
HPV type 16 E7 interacts directly with PKM2 and
promotes its dimeric state. This decreases PKM2’s affin-
ity for PEP in the final step of glycolysis and may be a
means of diverting glycolytic intermediates for anabolic
purposes while compensating for the decreased energy
production with upregulated glutamine metabolism [64,
65]. However, this phenomenon has yet to be examined
using modern techniques such as metabolite tracing that
could confirm this altered nutrient utilization. Addition-
ally, the HPV viral protein E2 has been shown to interact
directly with the mitochondrial membrane and induce
release of ROS as well as to upregulate HIF-1α [66].
Hepatitis B virus
HBV is a double-strand DNA virus associated with the
development of hepatocellular carcinoma (HCC). The
worldwide prevalence of hepatitis B infection is esti-
mated at 257 million people, with the virus and its com-
plications causing 887,000 deaths in 2015 [67]. In 2012,
420,000 new cancer cases were attributed to HBV [58].
HBV infection has broad effects on host cell metabol-
ism, impacting lipid, glucose, amino acid, nucleic acid,
vitamin, and bile acid metabolism [68, 69]. A combined
metabolomics and proteomics approach to evaluating
changes in HBV infection demonstrated evidence for up-
regulation of hexosamine biosynthesis, phosphatidylcho-
line biosynthesis, central carbon metabolism, nucleotide
synthesis, and oxidative stress [6]. HBV core protein
(HBc) has been shown to upregulate multiple metabolic
pathways, including glycolysis and amino acid metabolism
[70]. Studies have suggested potential specific metabolic
effects of HBV viral proteins on glucose metabolism. The
HBV pre-S2 mutant protein upregulates GLUT1 expres-
sion and plasma membrane localization [71]. HBV X pro-
tein (HBx) upregulates G6PD and expression of multiple
genes involved in gluconeogenesis [72, 73].
Fig. 3 Metabolic reprogramming by oncogenic viruses
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HBV transgenic mice have higher transcription of lipid
biosynthesis genes [74]. Similarly, transgenic mice with
the HBV pre-S2 mutant antigen exhibited increased lipid
droplet accumulation and upregulation of several lipo-
genic enzymes [7]. HBV X protein (HBx) has been
shown to activate lipid synthesis and uptake and inhibit
ApoB secretion [75–77].
Other metabolic changes induced by HBV infection in-
clude upregulation of proteins involved in the metabolism
of retinol, which is interesting because retinoic acid in the
presence of retinoic X receptor (RXRα) has been shown to
regulate HBV gene expression [78, 79]. HBV infection also
enhances proteins involved in the metabolism of choles-
terol and biosynthesis of bile acids [80].
Hepatitis C virus
HCV is a single-stranded RNA virus that is associated
with the development of HCC. HCV was estimated to
be linked to 170,000 new cases of cancer in 2012 [58]. In
contrast to the global predominance of HBV as an eti-
ology of HCC, in some areas, including Japan, Italy,
France, and Spain, the majority of HCC cases appear to
be associated with HCV infection. In the United States,
evidence of HCV infection is found in 30–50% of pa-
tients with HCC [81, 82].
HCV infection has been shown to alter metabolism at
both the cellular and whole organism level. At the cellu-
lar level, major metabolic changes include upregulation
of lipogenesis and altered lipid utilization, manipulation
of glucose uptake and metabolism, and induction of oxi-
dative stress through mitochondrial dysfunction [83].
Many of the HCV-induced alterations in lipid metabol-
ism stem from the HCV core protein. HCV core
protein-expressing transgenic mice develop hepatic stea-
tosis at grades correlative to the HCV core protein level,
and subsequent liver lesions with histologic similarity to
HCC, suggesting that the core protein plays a role in
lipid metabolism rewiring that occurs at an organ level
preceding HCC development [84, 85]. HCV core protein
within the cell accumulates in a globular pattern around
the lipid droplets by means of interaction with DGAT1,
and DGAT1−/− mice do not develop steatosis induced
by HCV core protein [86–88]. Studies have suggested
that HCV core protein can alter lipid metabolism
through inhibition of microsomal triglyceride transfer
protein (MTP), activation of the Srebp-1c promoter
(HCV nonstructural protein 2 has also been suggested
to perform this function), and increasing proteolytic
cleavage of sterol regulatory element binding proteins to
their mature forms (HCV nonstructural protein S4B has
also been suggested to play a role in this) among others
[89–92]. Additionally, transcriptomics studies suggest
that the HCV microRNA miR-146a-5p upregulates tran-
scription of genes involved in fatty acid metabolism [93].
HCV infection is associated with induction of oxida-
tive stress and altered maintenance of redox balance. In
HCV core protein transgenic mouse models, mice were
found to have core protein accumulation at the mito-
chondrial membrane, higher levels of liver ROS, lower
ratios of reduced to total glutathione, and increased
signs of oxidative damage, including higher levels of lipid
peroxidation and earlier signs of mtDNA damage [94,
95]. HCV-infected cells have increased superoxide pro-
duction [96], and studies suggest that the HCV core pro-
tein and HCV nonstructural proteins NS5A and NS3 are
capable of inducing increased ROS [97–100]. HCV core
protein may induce ROS by inhibiting mitochondrial
complex I, which disrupts the electron transport chain
and generates ROS [95]. HCV core protein interacts with
the mitochondrial chaperone protein prohibitin, increas-
ing its stability and levels but impairing its ability to
interact with cytochrome c oxidase (COX) subunits, po-
tentially resulting in disrupted COX assembly that could
lead to increased ROS [101]. HCV core protein increases
mitochondrial Ca2+ influx, which is thought to induce
ROS production [95, 102]. HCV infection increases ex-
pression of NADPH oxidases Nox1 and Nox4 via
TGFβ1, resulting in increased ROS production, and
HCV core on its own appears to increase ROS produc-
tion via TGFβ1-mediated increases in Nox4 expression
and activity [103, 104].
HCV infection perturbs glucose metabolism, resulting
in increased insulin resistance and gluconeogenesis. This
is manifested clinically in patients with HCV infection as
those with sustained responses to antiviral therapy dem-
onstrate decreased insulin resistance and increased IRS1/2
expression [105]. Transgenic mice with expression of
HCV core protein in the liver demonstrate evidence of in-
creased insulin resistance [106]. At the cellular level, HCV
core protein has been observed to increase IRS1 phos-
phorylation and impair insulin activation of Akt [107].
Core also decreases IRS1 and IRS2 levels and inhibits 6-
phosphofructo-2-kinase activation [108]. The HCV non-
structural protein NS5A has been found to increase
hepatic gluconeogenesis through induction of ROS, lead-
ing to increased PEPCK and G6Pase expression and
decreased glucokinase expression [109].
HCV is also capable of altering glutamine metabolism,
and recent studies suggest that HCV infection both
upregulates enzymes of glutaminolysis and induces glu-
tamine addiction in the infected cell for both cell growth
and for HCV viral replication [110].
Epstein-Barr virus
EBV is an oncogenic γ-herpesvirus associated with
multiple malignancies, most prominently lymphoma
but also nasopharyngeal carcinoma, gastric carcinoma,
and leiomyosarcoma, and an estimated 120,000 new
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cases of cancer were attributed to EBV infection in
2012 [58, 111].
EBV infection alters host cell glucose metabolism pri-
marily through viral protein LMP1. Studies suggest that
LMP1 promotes glycolysis via FGF2 and FGR1 activation
and that this mechanism is also important for the in-
fected cells’ transformation characteristics, including
proliferation, migration, and invasiveness [112]. LMP1
also enhances glycolysis by upregulating HK2, a change
that correlates with increased cell viability and prolifera-
tion. Increased HK2 expression was also noted in some
cases of EBV-associated NPC and was negatively corre-
lated with survival [113]. LMP1 enhances expression,
stability, and plasma localization of GLUT1, contributing
to increased glycolysis [114, 115]. Studies also suggest
that LMP1 may upregulate glycolysis by repressing HOX
genes [116]. LMP1 also promotes glycolysis by upregu-
lating PDK1 and PKM2 via upregulation of HIF-1α [117,
118]. LMP1 promotes HIF-1α stabilization by enhancing
the degradation of prolyl HIF-hydroxylases PHD1 and
PHD3 [119]. Additionally, the EBV viral proteins EBNA3
and EBNA5 bind to PHD2 and PHD1, respectively, per-
haps representing another mechanism by which EBV in-
fection stabilizes HIF-1α to promote glycolysis [120].
EBV infection also produces the miRNA EBV-miR-
Bart1-5P that has been shown to promote a glycolytic
phenotype [121].
EBV infection alters lipid metabolism in part through
EBV-encoded RNAs (EBERs), which leads to upregula-
tion of fatty acid synthase (FAS) and low-density lipo-
protein receptor (LDLR) [122]. During lytic reactivation,
expression of one of the EBV immediate-early proteins,
BRLF1, results in FAS upregulation [123].
Additionally, EBV infection-induced metabolic changes
appear to be linked to modulation of the immune re-
sponse, and studies suggest that LMP1 mediates upregula-
tion of GLUT1 resulting in increased cytokine secretion
and expansion of myeloid-derived suppressor cells [114].
Kaposi’s sarcoma-associated herpesvirus
KSHV, also known as human herpesvirus 8, is an onco-
genic γ-herpesvirus known to cause Kaposi’s sarcoma,
resulting in 44,000 new cancer cases in 2012, and is also
associated with primary effusion lymphoma (PEL) and
multicentric Castleman’s disease [58, 124, 125].
KSHV alters host cell glucose metabolism. KSHV infec-
tion promotes glycolysis by upregulating HIF-1α and its
glycolytic target genes, including PKM2, HK, GLUT1, and
PDK1, and by reducing mitochondrial biogenesis via tar-
geting of mitochondrial heat shock protein HSPA9, and
these changes result in increased cell growth [126–128].
Additionally, studies suggest that miRNAs produced dur-
ing latent KSHV infection are also secreted in exosomes
that infiltrate neighboring cells in the microenvironment,
inducing glycolysis in these cells and thereby supporting
the growth of the latently infected cells [129].
KSHV latent infection induces lipid droplet formation
and alters lipid metabolism by upregulating lipid biosyn-
thesis as well as peroxisome biosynthesis and associated
proteins involved in very long chain fatty acid metabol-
ism [8, 130, 131]. KSHV viral miRNAs also inhibit chol-
esterol synthesis, possibly suppressing cellular innate
immune functions [132].
Studies suggest that latent KSHV infection also upre-
gulates glutamine metabolism, inducing protein expres-
sion of the glutamine transporter SLC1A5 (ASCT2) as
well as MondoA and its downstream targets involved in
regulation of glutaminolysis and making the infected
cells reliant on glutaminolysis for survival [133]. Meta-
bolomics studies have demonstrated increased levels of
pentose phosphate pathway intermediates in KSHV-
infected cells, suggesting that the viral infection may also
alter nucleotide biosynthesis [8].
Human T-lymphotropic virus type 1
HTLV-1 is an oncogenic virus of the deltaretrovirus fam-
ily that is estimated to infect approximately 5–10 million
people worldwide and is linked to the development of
adult T-cell leukemia, estimated to be associated with
3000 new cases of cancer in 2015 [58, 134, 135].
While host cell metabolic factors, particularly the degree
of hypoxia, glycolytic function, and electron transport
chain function, appear to influence HTLV-1 reactivation
and plus-strand transcription, very little is known about
how HTLV-1 infection alters cellular metabolism [136].
Studies from over a decade ago suggest that GLUT1 can
function as a receptor for HTLV-1 to bind to cells, confer-
ring cell susceptibility to the virus, and that HTLV-1 sup-
presses glucose consumption and lactate production when
binding to GLUT1 [137, 138]. Unfortunately, there have
not been many other studies examining the effects of
HTLV-1 infection on metabolism, making this an area
with great potential for discovery.
Merkel cell polyomavirus
MCPyV is a relatively recently discovered oncogenic
polyomavirus. Despite MCPyV infection being widely
prevalent, ranging from 50 to 80% of the population de-
pending on age, its associated malignancy, Merkel cell
carcinoma (MCC), is rare [59, 139]. While little is yet
known about the metabolism of MCPyV infection, re-
cent studies utilizing transcriptomics have suggested that
the MCPyV small tumor antigen (ST) is able to promote
a glycolytic phenotype by upregulating multiple glyco-
lytic genes, including SLC16A1 (MCT1) and SLC2A1
(GLUT1) [140].
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Limitations of current studies and future directions
In addition to studies describing how viral infections
alter host cell metabolism, there have been studies
examining how the host cell metabolic environment af-
fects the progression of some oncogenic viral infections,
such as EBV. Studies have suggested that in early EBV
infection, metabolic stresses such as decreased mito-
chondrial respiration or autophagic imbalance present a
barrier to cell proliferation [141]. Additionally, hypoxia
is able to induce EBV lytic reactivation via binding of
HIF-1α to the promoter of the EBV lytic reactivation
gene BZLF1 [142]. Hypoxia also induces KSHV lytic rep-
lication through the interaction of viral proteins with
HIF-1α [143, 144]. Studies suggest that KSHV also relies
on different components of host cell metabolic infra-
structure for different stages of viral replication, with
glycolysis important for viral gene transcription, gluta-
minolysis important for viral protein translation, and
fatty acid synthesis important for virion assembly and
release [145]. Upregulation of glycolytic metabolism and
lipogenesis appears to be important for maintenance of
KSHV latently infected cells as inhibition of these pro-
cesses results in increased apoptosis in infected cells
compared to mock-infected cells [8, 146]. While this re-
view has focused on the effects of viral infections on me-
tabolism, the related question of how existing host cell
metabolism affects viral infections is also intriguing as
cell metabolic infrastructure can provide receptors for
viral access and metabolic sensors can act as transcrip-
tion factors for viral genes. It will be interesting to deter-
mine whether reliance on certain metabolic pathways
makes some cells more hospitable for certain viral infec-
tions than others.
In some studies, including several referenced in this
review, viral proteins are linked to major metabolic regu-
lators without demonstrating that this link is responsible
for a metabolic phenotype. For example, in addition to
the previously mentioned link to HIF-1α, many studies
have shown that EBV infection and its viral proteins are
linked to AMPK and MYC [147]. In another example,
HBV X protein (HBx) has been shown to activate major
metabolic regulators mTORC1 and AMPK [148]. Studies
have suggested that despite their well-established con-
nection with metabolism, major metabolic regulators
can have shifting levels of metabolic importance between
different forms of infection by a single virus such as
EBV [149]. This demonstrates the importance of directly
connecting suggested mechanisms with metabolic phe-
notypes to determine which are truly important meta-
bolic pathways during viral infection.
The studies discussed above have laid the groundwork
for understanding metabolic alterations by oncogenic vi-
ruses. One major question that remains is whether the
virally induced metabolic changes, which bear striking
similarity to metabolic perturbations in cancer cells, also
promote cellular transformation. Proving that these
changes are necessary or sufficient for transformation
will require well-designed in vivo studies. Careful mech-
anistic experiments using viral mutants are needed to
clarify the metabolic effects of specific viral proteins
expressed at physiological levels as well as to truly dem-
onstrate which metabolic changes are important for cell
transformation and how they contribute to oncogenesis.
Metabolic phenotypes that have been inferred by alter-
ations in metabolic enzymes should be examined using
LC-MS and metabolite tracing to strengthen our under-
standing of nutrient utilization during infection by vari-
ous viruses.
Viruses as cancer discovery tools and therapies
DNA viral proteins and tumor cell mutations converge
on many of the same molecular pathways to promote
viral or cellular replication, including anabolic pathways.
Key oncogenes and tumor suppressor genes, including
Src kinase, p53, PI3-kinase, and others, were originally
discovered by identifying host pathways that DNA viral
proteins interact with to promote viral replication [150].
While new tools are continually being developed to fur-
ther cancer research, cancer genome instability and
short evolutionary life-span make it difficult to distin-
guish passenger versus molecular drivers of tumorigen-
esis [150]. On the other hand, viruses, such as
adenoviruses, have evolved to be efficient and alter key
pathways in host cells that enable them to replicate ef-
fectively [150].
Since adenoviruses have undergone strong selective
pressure for efficiency, and they completely rely on host
cell machinery for replication, the specific metabolic
nodes they hijack for their replicative needs may repre-
sent especially important metabolic nodes for anabolism
(Fig. 4). As a proof-of-principle, a few years ago we
found that adenovirus infection increases GLS protein
levels and activity [12]. GLS is already a cancer metabol-
ism drug target—the GLS inhibitor CB-839 is currently
being used in clinical trials to treat certain types of solid
and hematological malignancies that also rely on GLS
activity. We found that treatment of adenovirus infected
cells with CB-839 reduces viral titers. Additionally, we
also found that adenovirus infection selectively increases
expression of asparagine synthetase (ASNS), which is
critical for proliferation of various cancer cell lines
through its role as an amino acid exchange factor [151].
Adenovirus infection increases ASNS protein expression
and knocking down ASNS levels decreases adenovirus
replication (unpublished observation). These results are
examples that metabolic enzymes and pathways critical
for optimal virus replication may also be important for
cancer cell proliferation. Understanding how a rapidly
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replicating virus like adenovirus alters host cell metabol-
ism during infection will likely reveal critical anabolic
nodes that are important in different cancers, just as un-
derstanding how viruses reprogram host cell signaling
and transcriptional machinery helped identify key onco-
genes and tumor suppressor genes in the 1970s and
1980s [150].
Oncolytic viruses
Oncolytic viruses are viruses that are engineered to se-
lectively kill tumor cells and trigger systemic anti-tumor
immunity [152]. Compared to traditional approaches to
treat cancers, use of oncolytic viruses as a treatment
strategy may be advantageous in that normal tissues
should not suffer adverse effects to the same extent as
with chemotherapeutics due to increased specificity for
tumor tissue. Additionally, direct cell lysis by oncolytic
viruses would avoid the problem of drug resistance
[153]. Despite many potential advantages, however,
safety concerns have prevented widespread use of onco-
lytic viruses as a cancer treatment.
The specificity of tumor cell killing by oncolytic viruses
is based on the virus’s requirement for cell functions
idiosyncratic to cancer cells, which can include metabolic
functions. For instance, adenoviral mutants that are un-
able to perturb cell cycle machinery, including p53 and
retinoblastoma (Rb), needed for replication may replicate
in tumor cells that already have dysregulated signaling of
both these proteins [150]. Oncolytic virus design could
benefit from incorporation of metabolic strategies to
achieve better cancer cell specificity. For instance, many
DNA viruses have evolved mechanisms to increase dNTP
levels in host cells since dNTP levels can be low in cells
that are not cycling actively [154]. Oncolytic viruses
that lack viral proteins responsible for increased
dNTP synthesis or acquisition would be predicted to
replicate only in cells that have upregulated dNTP
metabolism (i.e., cancer cells). Consistently, the D68A
mutant form of adenovirus type 5 deficient in
E4ORF1 activation of MYC and increased nucleotide
biosynthesis was deficient in replication in primary
lung epithelial cells but not in immortalized breast
epithelial cells that had enhanced nucleotide biosyn-
thesis rates [2]. A stronger understanding of the
mechanisms by which viral proteins perturb metabol-
ism in host cells will be helpful for oncolytic virus
Fig. 4 Comparison of a cell infected with wild-type adenovirus and a cancer cell. While cancer cells have numerous mutations and perturbation
of whole metabolic pathways (green), adenovirus-infected cells upregulate only key metabolic nodes for virion replication
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design and will improve their selectivity for targeted
replication and killing of tumor but not normal cells.
Conclusions and future directions
While many studies have demonstrated that viruses re-
program cell metabolism and rely on metabolic changes
for optimal virus replication in vitro, significant work re-
mains to determine mechanistically what viral proteins
interact with host cell machinery to induce such alter-
ations and characterize whether the same metabolic per-
turbations occur during infection in vivo. Additionally, it
will be interesting for future studies to determine
whether there is different viral affinity for and replication
across tissue types depending on the metabolic environ-
ment; whether differential metabolic reprogramming by
a virus across multiple species impacts how specific spe-
cies cope with viral replication; and whether or not viral-
induced metabolic reprogramming contributes to onco-
genesis. The future is certainly ripe for discovery in the
viral metabolism field.
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